FOCUSED LEADERSHIP

Conducting Administrative success.

Meet the AVITA Medical Management Team

AVITA Medical’s leadership team is comprised of experienced industry executives who bring a critical set of skills to the organization to support long-term growth.

DR. MICHAEL PERRY

Chief Executive Officer

Dr. Mike S. Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status.

Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014.

With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.

DAVID MCINTYRE

Chief Financial Officer

A seasoned executive with more than 20 years of experience, Mr. McIntyre has served in senior financial,legal and operational roles across multinational and growth-stage entities. Most recently, Mr. McIntyre served as a Partner with Apple Tree Partners (ATP), a multibillion-dollar venture capture and growth equity fund focused exclusively on life sciences. At ATP Mr. McIntyre was responsible for ATP’s medical device portfolio, together with various operating and Board functions, including acting as Executive Vice President, Chief Financial Officer and Head of Technical Operations at Braeburn, Inc.

Prior to ATP, Mr. McIntyre was Executive Vice President, Chief Financial Officer and Chief Operating Officer at HeartWare® International, Inc. (previously ASX:HIN; NASDAQ: HTWR) where he oversaw HeartWare’s financial, supply chain and operating functions as it transitioned from pre-clinical stage through commercialization across more than 20 countries. Prior to HeartWare, Mr. McIntyre practiced as a senior attorney in private practice specializing in corporate, mergers and acquisitions and equity capital markets with Baker & McKenzie and KPMG as well as holding various senior financial roles in multi-national companies, including within the Rio Tinto Group of companies.

ERIN LIBERTO

Chief Commercial Officer

Erin Liberto, Chief Commercial Officer (CCO), has more than 15 years of multifaceted global commercial experience developing, launching, managing, and optimizing healthcare portfolios with products that span therapeutic and aesthetic indications for international organizations including Allergan and Johnson & Johnson.

Mrs. Liberto’s proficiency in long-term strategic planning has led to 12 successful product launches across the U.S, Europe, and Asia Pacific. Her expertise in developing pipeline plans, new indications, geographic expansion and recognition of whitespace promotes her rapid identification of business development opportunities, and the formulation of corresponding portfolio and brand strategies to advance diverse geographies that drive revenue growth and global market share.

Erin holds an International MBA with a concentration in Global Marketing from Thunderbird School of Global Management in Arizona and a Bachelor of Commerce from McMaster University in Canada.

TIMOTHY ROONEY

Chief Administrative Officer

Tim Rooney joined AVITA Medical as Chief Financial Officer (CFO) / Chief Operating Officer (COO) in 2012, leading various key executive roles including interim CEO from 2013 to 2015. Tim is currently the Chief Administrative Officer (CAO) and Interim Chief Financial Officer.

Mr. Rooney holds Finance and Economics degrees, and over 25 years of experience in senior finance and operations management in medical devices and pharmaceutical wholesale distribution, including an ownership role at PDI Enterprises, Inc., a pharmaceutical wholesale distributor, where he served as CFO/COO, and managed their growth from a regionally-operated upstart to a market-leading national presence, growing revenue from $5 million to $430 million.

ANDREW QUICK

Chief Technology Officer

Andrew Quick joined AVITA Medical in 2010 and currently holds the position of Chief Technology Officer, adding more than 25 years of experience in medical device design, development, clinical research and medical affairs to our executive management team. Mr. Quick has previously held leadership positions in the development of diagnostic instrumentation and active implantable therapeutics, including most recently with Boston Scientific Neuromodulation / Advanced Bionics where he led U.S. investigational device and post-market clinical research in the cochlear implant business. Andrew holds Bachelor of Science and Master of Science degrees in Biomedical Engineering from Boston University.

DONNA SHIROMA

General Counsel

Donna Shiroma, General Counsel, brings more than 20 years of legal and compliance experience in the pharmaceutical and medical device industries and has played an instrumental role in transitioning companies from clinical to commercial entities. Prior to joining AVITA Medical, she served in roles of increasing responsibility as corporate counsel, general counsel, vice president of legal, chief privacy and compliance officer, and chief commercial officer for Ascend Therapeutics, PDL BioPharma, and several Johnson & Johnson companies.

Revolutionizing Medical Leadership.

Meet the AVITA Medical Board of Directors

At AVITA Medical, our board members empower our culture, diversity, and advancement as global leaders in a regenerative medicine company. Collectively, our advisors provide innovative solutions and industry-leading guidance to focus on patient care and medical successes made possible from their direction and insistence that only results change the way exceptional care is administered.

LOU PANACCIO

Chairman

Mr. Panaccio was appointed as AVITA Medical Chairman of the Board in July 2014 with more than 30 years of executive leadership skills in healthcare and life sciences experience, including developing company concepts through finished commercialization.
Mr. Panaccio is positioned on additional Boards including Non-Executive Director of ASX50 company, one of the world’s largest medical diagnostics companies; Sonic Healthcare Limited since 2005; Non-Executive Director Unison Housing Limited; Non-Executive Chairman of Genera Biosystems Limited; and Non-Executive Director Rhythm Biosciences Limited. Mr. Panaccio’s past executive and board roles includ Melbourne Pathology Group, Monash IVF Group, Health Networks Australia Group and Primelife Corporation Limited.

JEREMY CURNOCK COOK

Non-Executive Director

Mr. Curnock Cook was appointed to the AVITA Medical Board in October 2012. As the former leader of Rothschild Asset Management, a life science private equity firm, Mr. Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market, and the conception and launch of the International Biotechnology Trust.

As current Managing Director of Bioscience Managers Pty Ltd, Mr. Curnock Cook is responsible for the BSM Asia Pacific Healthcare Fund and is appointed to the Boards of AmpliPhi Bioscience Corporation Inc. (since 1995); Rex Bionics Pty Ltd (since 2017); International Bioscience Managers Ltd (since 2000); Adherium Ltd (since 2015); SummatiX Ltd (since 2017) and Arecor Ltd (since 2018). Previous appointments included Eacom Timber Corporation, Sirna Therapeutics Inc, and Biocompatibles International PLC.

DR. MICHAEL PERRY

Chief Executive Officer & Executive Director

Dr. Mike Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status.

Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014.

With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.

LOUIS DRAPEAU

Non-Executive Director

Mr. Drapeau was appointed to the AVITA Medical Board in January 2016.

Mr. Drapeau’s current positions include Independent Director at AmphliPhi Biosciences Corporation (NYSE) and Independent Director at Surface Pharmaceuticals Inc; His previous senior positions included roles with InSite Vision Inc as CFO and Vice President; Independent Director at Bio-Rad Laboratories, Inc. (NYSE). Nektar Therapeutics as Senior Vice President and CFO, BioMarin Pharmaceutical, Inc. as Senior Vice President and CFO; Audit Partner at Arthur Andersen, LLP; Independent Director at InterMune, Inc. (NASDAQ); Bionovo, Inc. (NASDAQ); and Inflazyme Pharmaceuticals LTD (TSE).

Mr. Drapeau has a bachelor of science in Mechanical Engineering and an MBA, both from Stanford University.

DAMIEN MCDONALD

Non-Executive Director

Mr. McDonald was appointed to the AVITA Medical Board in January 2016. He holds an MBA from the Institute for Management Development (IMD) in Lausanne, Switzerland, a Master of Science in International Economics from the University of Wales, U.K.; a Bachelor of Economics degree and a Bachelor of Pharmacy degree, both from the University of Queensland, Australia.

Mr. McDonald is currently the Chief Executive Officer of LivaNova, a NASDAQ listed Medtech innovator. His previous roles included COO of LivaNova; Group Executive and Corporate Vice President at Danaher Corporation, leading a $1.5 billion group of dental consumables company; Group President at Kerr; Spine Division Leader at Zimmer; and J&J’s Medical Device Franchises, marketing the $2.5 billion medical device unit.

PROFESSOR SUZANNE CROWE

Non-Executive Director

Appointed to the AVITA Medical Board in January 2016, Prof. Crowe holds medical and MD degrees from Monash University, an internal medicine specialist qualification in Infectious Diseases from the Royal Australasian College of Physicians, and a Diploma in Medical Laboratory Technology from the Royal Melbourne Institute of Technology.

Prof. Crowe’s current positions include, Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne; Adjunct Professor of Medicine and Infectious Diseases at Monash University, Melbourne; Member of the Australian Institute of Company Directors; Non-Executive Director of St Vincent’s Health Australia; and Appointed Member of the Order of Australia (AM) in 2011, recognizing her medical research service in HIV/AIDS.

This website stores cookies on your computer. These cookies are used to improve your website experience and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our privacy policy.